Janssen’s psoriasis candidate guselkumab Shows Encouraging Last-Study Results-The results from Phase 3 clinical Trial, VOYAGE1, evaluating Janssen’s $JNJ guselkumab efficacy in comparison to AbbVie’s $ABBV HUMIRA (adalimumab) among adult patients with moderate-to-severe plaque psoriasis showed that the former is better. The data was presented over the weekend at the 25th European Academy of Dermatology and Venerology Congress in Vienna, Austria. GuselKumab was administered through subcutaneous injection at weeks 0 and 4 then every 8 weeks subsequently.
Aralez Introduces YOSPRALA in the U.S.-Aralez Pharmaceuticals $ARLZ launched YOSPRALA in the U.S. for secondary prevention of cardiovascular and cerebrovascular events for patients at risk of aspirin-linked gastric ulcers. The once-a-day dose is the only prescription fixed-dose combination of aspirin, an anti-platelet agent, and omeprazole, a proton pump inhibitor (PPI), in the U.S. YOSPRALA is being promoted by 110 sales representatives in the U.S. and is currently available in the wholesale chain.
Jazz Pharma Commences Rolling NDA for Leukemia Candidate Vyxeos-Jazz Pharmaceuticals $JAZZ initiated the rolling submission of its New Drug Application (NDA) to the FDA seeking approval for Vyxeos (cytarabine and daunorubicin liposome injection) for the treatment of acute myeloid leukemia (AML), a Breakthrough Therapy-designated indication. The company anticipates completing the filing in early 2017. The drug-maker took the rights to Vyxeos through its acquisition of Celator Pharmaceuticals, earlier in July.
Ironwood’s ZURAMPIC Now Available in U.S. Pharmacies-Ironwood Pharmaceuticals $IRWD announced that ZURAMPIC, a once-a-daily oral tablet taken in combination with a Xanthine oxidise inhibitor (XOI) for the treatment of hyperuricemia, is now available in pharmacies throughout the U.S. Hyperuricemia is a condition where high serum uric acid (sUA) levels in the blood are found, which is associated with gout in patients who have not achieved target sUA levels with an XOI alone.
GlobeImmune Climbs on Hopes of Phase 2 Data-Lightly traded nano-cap stock GlobeImmune Inc $GBIM gained 8% on Monday, continuing with its uptrend that started on September 21. The stock has vaulted 65% since then, mainly on optimism surrounding the positive 48-week data from a Phase 2 Clinical Trial evaluating GS-4774, a therapeutic HBV vaccine candidate being developed by Gilead Sciences ($GILD). The outcome will be presented at the Liver Meeting in Boston on November 14.